is desirable ), while meeting quality requirements .
Avantor ’ s J T Baker Direct Dispense packaging was recently developed to meet the customer need for automation and speed in plants . These disposable bags increase speed of production by allowing for assembly line type mixing , flexible bag sizes and no clumping of excipients , reducing manual intervention . The packaging is increasingly being adopted by customers around the globe who are sensitive to quality and time .
How has been the company ' s performance in India ( including percentage of growth YOY ) since last few years ?
While Avantor , as a private company , does not disclose financial information , I can tell you that since 2011 Avantor India revenue has grown at a healthy pace , with CAGR significantly exceeding the industry trend of 6- 7 percent growth annually .
Please share with us your few unique experiences / learnings ( customer behaviour , regulatory dealings or partners ) in Indian market .
India has become a sourcing and manufacturing hub for generic drugs . Advanced countries , including the U . S ., Europe and Japan , have very strict regulations ( e . g ., regulations established by the USFDA , MHRA UK , TGA Australia , WHO GMP , etc .). To meet regulatory muster , many pharma companies that sell into these advanced economies are seeking excipient suppliers that offer cGMP products that comply with Pharmacopeia specifications .
Avantor ’ s capabilities and
“
Avantor ’ s capabilities and experience in providing global regulatory documentation support at the product development stage has helped us become a preferred supplier .
experience in providing global regulatory documentation support at the product development stage has helped us become a preferred supplier .
How big is the market and how do you look at its potential opportunities ?
Our J T Baker HPLE sugars are used in the manufacturing of biosimilars and vaccines . This market is at a nascent stage . The current base market is around 1.5 - 2 MT and should grow at 18 percent per year .
What kind of future outlook do you have for your company , as well as the industry ?
The pharmaceuticals industry in India is going through a major transformation , the key elements of which are :
• Small molecule drug manufacturers are targeting markets in the developed world to get a better return on their investments ;
• Indian regulators are tightening quality standards in pharma sourcing and manufacturing ;
• The FDA is increasing scrutiny of cGMP manufacturing for Indian generic / biosimilar exporters , including issuing warning letters , shutting down plants , etc .;
• Top Indian pharmaceutical companies are entering the CMO space and partnering with global pharma leaders ; and
• Generic manufacturers are launching biosimilar offshoots to capture a higher-value customer segment ( e . g ., Oncology , Cardio etc .).
Due to these factors , pharma companies need excipients of the highest quality , which is exactly what we provide at Avantor . Some of our new products also help in reducing time and improving yield , giving our customers an edge to capture market share .
Avantor ’ s advantage is the completeness of the support ecosystem we provide to customers : world-class cGMP manufacturing , high quality standards , technical support and product development through scientists and labs ( including five labs in APAC ), key account managers on the ground , and an effective supply chain through warehouses , planners and dealers . Due to these factors — and the high-growth markets in which we operate — we are extremely confident in our ability to generate industry-leading growth , while meeting the unique needs of our global customers .
BIOVOICENEWS . COM 31